UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Dr. Reddy's Laboratories After Disappointing 3Q
In a report published Friday, Citigroup reiterated its Buy rating on Dr. Reddy's Laboratories (NYSE: RDY), and raised its price target to $39.36.
Citigroup noted, “We rate DRL Buy with a Target Price of $39.36. REDY, in our view, is among the best placed to capitalize on the multiple growth drivers for pharma over the next 3-4 years. We expect the U.S. (limited competition oppys, rising share in old products), India (sales force addition, new launches) and Russia (OTC push, fast growing market) to drive growth in the medium term, while biosimilars and the emerging markets deal with GSK contribute longer-term. With several catalysts lined up & attractive valuations, we think it is a good time to buy the stock.”
Dr. Reddy's Laboratories closed on Thursday at $34.82.
Latest Ratings for RDY
|Jul 2016||Credit Suisse||Downgrades||Neutral||Underweight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.